Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study

European Journal of Endocrinology

Volumn 156, Issue 1, 2007, Pages 33-40

  Salvi, Mario ^a   Vannucchi, Guia ^a   Campi, Irene ^a   Currò, Nicola ^a   Dazzi, Davide ^c   Simonetta, Simona ^a   Bonara, Paola ^a   Rossi, Stefania ^b   Sina, Clara ^a   Guastella, Claudio ^a   Ratiglia, Roberto ^a   Beck Peccoz, Paola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Department of Medicine Surgery and Dentistry ^*  (Italy)

^c Ospedale di Fidenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTACID AGENT; BENZODIAZEPINE; CD20 ANTIGEN; CHLORPHENIRAMINE; GAMMA GLUTAMYLTRANSFERASE; HYDROCORTISONE; METFORMIN; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; THIAMAZOLE; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; THYROID HORMONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BODY TEMPERATURE; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIET THERAPY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DYSPEPSIA; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE CARE; FEMALE; FLUSHING; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GOITER; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTHYROIDISM; INSOMNIA; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NASAL PRURITUS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROAT IRRITATION; THYROID FUNCTION; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; THYROID FUNCTION TEST;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 33847727902     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02325     Document Type: Article

References (36)

1. Zakarija M & McKenzie JM. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinology and Metabolism Clinics of North America 1987 16 343-363.
2. Rees Smith B, McLachlan SM & Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocrine Review 1988 8 106-121.
3. Segundo C, Rodriguez C, Garcia-Poley A, Aguilar M, Gavilan I, Bellas C & Brieva JA. Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments. Thyroid 2001 11 525-530.
4. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D & Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998 8 119-124.
5. Balm RS. Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1939-1946.
6. Valyasevi RW, Harteneck DA, Dutton CM & Balm RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. Journal of Clinical Endocrinology and Metabolism 2002 87 2352-2358.
7. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP & Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. Journal of Biological Chemistry 1998 273 29615-29625.
8. Mikozami T, Salvi M & Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? Journal of Endocrinological Investigation 2004 27 221.
9. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM & Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clinical Endocrinology 2000 52 267-271.
10. De Bellis A, Bizzarro A, Conte M, Solimeno C, Perrino S, Sansone D, Guaglione M, Wall JR & Bellastella A. Relationship between longitudinal behaviour of some markers of eye auto-immunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clinical Endocrinology 2003 59 388-395.
11. Kubota S, Obye H, Nishihara E, Kudo, T, Ito M, Fukata S, Amino N Kuma K & Miyauchi A. Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease. Endocrine Journal 2005 52 735-741.
12. Eckstein AK, Plicht M, Hildegard L, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J & Morgenthaler NG. TSH-receptor autoantibodies are independent risk farctors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. Journal of Clinical Endocrinology and Metabolism 2006 91 3464-3470.
13. Tsokos GC. B cells be gone - B-cell depletion in the treatment of rheumatoid arthritis. New England Journal of Medicine 2004 350 2546-2548.
14. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation 2006 6 859-866.
15. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara. P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R & Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid brammosuppression. European Journal of Endocrinology 2006 154 511-517.
16. El Fassi D, Nielsen CH, Hasselbalch HC & Hegedus L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology 2006 154 623-632.
17. Mourits MP, Prummel MF, Wiersinga WM & Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy, Clinical Endocrinology 1997 47 9-14.
18. Werner SC. Classification of the eye changes of Graves' disease. Journal of Clinical Endocrinology and Metabolism 1969 29 982-984.
19. Gorman CA. The measurement of change in Graves' ophthalmopathy. Thyroid 1998 8 539-543.
20. Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, Nishimura H, Noshida H & Kaise N. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy. Endocrine Journal 1993 40 63-72.
21. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P. Cartei F & Nardi M. Pinchera A comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radio-therapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology and Metabolism 2001 86 3562-3567.
22. Kahaly GJ, Pitz S, Hommel G & Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism 2005 90 5234-5240.
23. Davidson A & Diamond B. Autoimmune diseases. New England Journal of Medicine 2001 345 340-350.
24. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA & Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Human Antibodies 2004 13 55-62.
25. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ & Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus crythematosus. Arthritis & Rheumatism 2004 50 3580-3590.
26. Male D, Cooke A, Owen M, Trowsdale J & Champion B. Antigen receptor molecules Advanced Immunology, pp. 2.1-2.2, London: Mosby, 1996.
27. Armengol MP, Juan M, Lucas-Martin A, Fernandez-Figueras MT, Jaraquemada D, Gallart T & Pujol-Borrel R. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gone expression in chemokine-containing active intrathyroidal germinal centers. American Journal of Pathology 2001 159 861-873.
28. Anolik JH, Campbell D, Felgar RE, Rosenblatt J, Young F, Sanz I & Looney RJ. B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism, 2002 (Suppl 9) S717 (Abstract).
29. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM & Shaw T. Efficacy of 13-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 2004 350 2572-2581.
30. Drexhage HA. Are there more than antibodies to the thryoid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology 2006 147 9-12.
31. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L & Pinchera A. Disappearance of Immoral thyroid autobiamunity after complete removal of thyroid antigens. Annals of Internal Medicine 2003 139 346-351.
32. Rhen T & Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. New England Journal of Medicine 2005 353 1711-1723.
33. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR & Roti E. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cygarette smoking. European Journal of Endocrinology 2000 143 197-202.
34. Han R & Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1 beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 2006 147 13-19.
35. Rodriguez-Pinto D. B cells as antigen presenting cells. Cellular Immunology 2005 238 67-75.
36. El Fassi D, Nielsen CH, Hasselbalch HC & Hegedus L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006 16 709-710 (Letter).